Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › HIV-associated neurocognitive disorder

HIV-associated neurocognitive disorder

Subtypes of HIV-associated neurocognitive disorder

AIDS 3 Acquired Immunodeficiency Syndrome 0

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for HIV-associated neurocognitive disorder

2 trials tracked for HIV-associated neurocognitive disorder.

2Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 1 Other / NA 1
  1. Phase 2 Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder Completed
  2. N/A Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Secondary analysis of HIV trial links hematologic factors to neurocognitive disorder risk in substance users
Diabetes & Endocrinology RCT
Secondary analysis of HIV trial links hematologic factors to neurocognitive disorder risk in substance users HIV Brain Fog Tied to Blood Levels and Daily Habits
This secondary analysis of a randomized clinical trial evaluated 801 people with HIV who use substances across 11 U.S. hospitals. The study …
Lower hemoglobin and recent alcohol use raise brain fog risk in people with HIV who use substances.
May 7, 2026
Systematic review finds intestinal microenvironment abnormalities are more severe in HIV immunological non-responders compared to responders
Allergy & Immunology Sys. Review
Systematic review finds intestinal microenvironment abnormalities are more severe in HIV immunological non-responders compared to responders HIV Treatment Leaves Some Patients Behind. Here's Why
This systematic review evaluated intestinal immune and microbial differences between people living with HIV (PLWH) classified as immunologic…
Some HIV patients stay vulnerable to illness even after years of successful treatment because their damaged gut fails to rebuild immunity.
Frontiers Apr 16, 2026
Nevirapine plus lamivudine and zidovudine improved lymphocyte counts and reduced adverse effects versus efavirenz in HIV patients
Infectious Disease RCT
Nevirapine plus lamivudine and zidovudine improved lymphocyte counts and reduced adverse effects versus efavirenz in HIV patients New HIV drug combo showed fewer side effects and better immune markers in small trial
This randomized controlled trial enrolled 100 patients with HIV/AIDS in a hospital setting.
A new HIV drug combo boosted immune cells and caused fewer side effects than the standard alternative in a recent trial.
NEJM Apr 14, 2026
Galantamine showed no cognitive benefit in people with HIV-associated neurocognitive disorders
Infectious Disease RCT
Galantamine showed no cognitive benefit in people with HIV-associated neurocognitive disorders Why Galantamine Failed to Help
In a double-blind, randomized, placebo-controlled crossover study, people with HIV on antiretroviral therapy received galantamine or placebo…
Galantamine, a drug used for memory loss, did not improve brain fog in people with HIV, even though it increased a key inflammation marker.
Apr 12, 2026
HIV/AIDS continues disproportionate impact on U.S. Black or African American population
Allergy & Immunology
HIV/AIDS continues disproportionate impact on U.S. Black or African American population HIV and AIDS continue to disproportionately affect Black Americans, awareness day notes
A non-research announcement for National Black HIV/AIDS Awareness Day notes the continuing disproportionate impact of HIV infection and AIDS…
National Black HIV/AIDS Awareness Day highlights that HIV and AIDS continue to disproportionately affect Black or African American people in…
CDC Apr 4, 2026